Comparative Efficacy of Voclosporin in Combination With Mycophenolate Mofetil Versus Other Treatments in Active Lupus Nephritis: Systematic Review and Network Meta-Analysis (ISPOR-EU 2023) - Oct 4, 2023 - Abstract #CO189; Pres time: Nov 15, 2023; 09:00 AM - 11:30 AM; "ORs for CR favored VCS+MMF and belimumab when compared against the network reference of MMF (ORs were, 2.67; [95% CrI: 1.73-4.15] and 1.75; [95% CrI: 1.05-2.95]). Statistical significance was not reached for other calcineurin inhibitors including tacrolimus, both monotherapy (OR, 0.81; 95% CrI: 0.49-1.33) and in combination with MMF (OR, 1.10; 95% CrI: 0.51-2.37), and ciclosporin (OR, 1.35; 95% CrI: 0.24-9.04)... This analysis suggests that VCS+MMF was ranked the highest (SUCRA: 96%) for achieving CR in active LN compared to other therapies identified in this SLR. This NMA highlights the challenges faced when performing comparative analysis in LN, including: imbalances in potential treatment effect modifiers, heterogenous outcome definitions and follow-up, and quality of evidence (e.g., small sample size). Therefore, results from NMAs in LN should be interpreted with caution."
Combination therapy • Retrospective data • Review • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Lambton M1; Farrington E2; Clamp D2; Badgujar L3; Blaikie T4; Ektare V3
|